Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The production and sales of a novel leukemia medicine in South Korea has received public health agency's nod.
Subscribe to our email newsletter
According to Korea Food and Drug Administration (KFDA), Supect, a drug manufactured by Ilyang Pharmaceutical has been approved to treat leukemia in those resistant to currently available anti-leukemia treatment Gleevec drug, xinhuanet.com reported citing Yonhap News Agency.
The increased demand for the new treatment has been observed due to the rise in the number of patients becoming resistant to Gleevec.
Clinical data demonstrated that Supect is safer than Gleevec and causes no side effects such as cardiotoxicity and pulmonary edema, xinhuanet.com added, citing Yonhap.